Investor Presentation H1 2023

44 Investor presentation First six months of 2023 Novo Nordisk has a leadership position within the growing diabetes market Novo NordiskⓇ Global diabetes market by treatment class¹ Novo Nordisk remains global diabetes value market leader Novo Nordisk market share and share of growth DKK billion 500 Market CAGR: 10% 400 60% 11% 13% 13% 14% 14% 21% 21% 21% 23% 24% 40% 38% 36% 300 CAGR: -3% CAGR: 33% 38% 36% 35% 30% 29% 200 CAGR: -4% 20% 33% 29% 100 30% 31% 31% 32% 33% CAGR: 29% 0 2018 0% 2019 2020 2021 2022 H1 2021 H2 2021 H1 2022 H2 2022 H1 2023 May May 2020 2023 GLP-1 Insulin SGLT-2i DPP-4i Company A Company B Others Novo Nordisk -NN market share -NN share of growth -Market growth (right axis) -NN growth (right axis) 1 Data is based on company reported sales. Data does not include generic metformin, sulphonylureas or thiazolidinedione NN: Novo Nordisk Source: IQVIA MAT, May 2023 value figures Note: IQVIA data can be inflated due to use of list prices in the US. Due to contractual obligations competitor names are not disclosed. Company A and B represent actual companies

View entire presentation